Implementing radiation oncology pathways at Dana-Farber Cancer Institute/Brigham and Women’s Hospital.

Authors

null

Victoria Hayne

Dana-Farber Cancer Institute, Boston, MA

Victoria Hayne, Leah A. Stein, Carole Kathleen Tremonti, Elizabeth H. Baldini, John G. Phillips, Susanna C. Hilfer, David Michael Jackman, Julia Cooper Hall, Teresa L. Greenberg, Joanna M. Hamilton, Joseph O. Jacobson, Neil E. Martin

Organizations

Dana-Farber Cancer Institute, Boston, MA, Brigham & Women's Hospital, Boston, MA, Dana-Farber Cancer Institute/ Brigham & Women's Hospital, Boston, MA

Research Funding

Other

Background: Modern cancer care faces increasing complexity and the challenge of delivering consistent, high-quality care across growing networks. Dana-Farber Pathways address these concerns by translating expert content into treatment algorithms delivered through a web-based platform and implemented across the network. We had previously built 31 Medical Oncology (MO) pathways. Our goal was to build and implement Radiation Oncology (RO) pathways for common cancer conditions in 18 months. Methods: Partnering with lead clinicians from each disease group, we chose the most appropriate framework for each pathway: expand previously established RO pathway; use corresponding MO pathway; or if no framework was available, develop RO pathway in its entirety. We worked with each disease group to gain consensus about the recommended on-pathway selections that reflect the latest research and institutional standard of care. Implementation consisted of pre- and post-launch department communications about metric goals and individual provider training on the system. Because the program was launched without provider incentivization, the usage rate goal was navigations for at least 25% of patients receiving radiation treatment. The on-pathway rate goal range was 70-80%. Results: We exceeded our goal: we built and implemented 25 pathways in 12 months and constructed all 27 pathways in 18 months. We have met both key rate goals across all disease pathways since time of launch: usage rate is 63%; on-pathway rate is 85% (39 providers across 3 sites). Conclusions: A preliminary analysis of RO Pathway data demonstrates collective adoption across all sites. Qualitative surveys show it to be a useful resource in radiation treatment decision-making and in palliative care service. We will continue to analyze the use of RO Pathways and develop strategies to collaborate with MO to further guide multi-disciplinary decision-making.

Cumulative RO On-Pathway Rates of Phase I Pathways (6 Months)

Disease Center (Pathways)On-Pathway Rate (Raw Navigations)
GI (Esophageal, Gastric, Rectal)74% (50)
GU (Prostate)92% (261)
Sarcoma67% (43)
Lymphomas (Hodgkin, Non-Hodgkin)84% (88)
Thoracic (NSCLC, SCLC)69% (173)
Breast95% (366)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B: Projects Relating to Patient Experience; Projects Relating to Safety; Technology and Innovation in Quality of Care

Track

Projects Relating to Patient Experience,Projects Relating to Safety,Technology and Innovation in Quality of Care

Sub Track

Use of Clinical Pathways

Citation

J Clin Oncol 36, 2018 (suppl 30; abstr 301)

DOI

10.1200/JCO.2018.36.30_suppl.301

Abstract #

301

Poster Bd #

N7

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Quality Care Symposium

Impact of declared wildfire disasters on survival of lung cancer patients undergoing radiation treatment.

First Author: Katie Lichter

Abstract

2023 ASCO Quality Care Symposium

Understanding radiation treatment terminations as an element of quality.

First Author: William Chun-Ying Chen